# US 2006/0051365 A1 · Immunogenic composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051365 A1
- Document ID: US20060051365A1
- Status: Published application
- Kind: A1
- Application number: 10/520,698
- Filed: 2003-09-07
- Published: 2006-03-09
- Earliest claimed: 2002-07-10
- Inventors: Andre Gorenflot; Eric Precigout; Stephane Delbecq; Theodorus Schetters
- Web page: https://patentgrep.com/patent/US20060051365A1

## CPC

- A61K 39/018: Babesia antigens, e.g. Theileria antigens
- A61K 39/012: Coccidia antigens
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/6031: {Proteins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides an immunogenic composition comprising a fusion protein and a saponin adjuvant. The fusion protein comprises a heterologous hydrophobic peptide that is fused to the N-terminus and/or to the C-terminus of a core polypeptide. The core polypeptide comprises at least one protective epitope. The saponin adjuvant in this composition is present in a free form. Also provided are vaccines comprising the immunogenic composition and optionally an additional immunoactive component. Methods for the preparation of such vaccines, and use of the immunogenic composition for the manufacture of a vaccine are provided as well.

## Claims

### Claim 1

An immunogenic composition comprising a fusion protein and a saponin adjuvant, characterized in that the fusion protein comprises a heterologous hydrophobic peptide which is fused to the N-terminus and/or to the C-terminus of a core polypeptide, the core polypeptide comprising at least one protective epitope, the saponin adjuvant being in a free form.

### Claim 2 (depends on 1)

The immunogenic composition according to claim 1, characterized in that the core polypeptide is a component of a protein of an organism of the phylum Apicomplexa.

### Claim 3 (depends on 2)

The immunogenic composition according to claim 2, characterized in that the core polypeptide is a component of a protein of an organism of the Piroplasmida or of the class Coccidia.

### Claim 4 (depends on 3)

The immunogenic composition according to claim 3, characterized in that the core polypeptide is a component of a protein of an organism of the genera Eimeria or Babesia.

### Claim 5 (depends on 1)

The immunogenic composition according to claim 1, characterized in that the heterologous hydrophobic peptide is from an N-terminal hydrophobic sequence.

### Claim 6 (depends on 1, 2, 3, 4)

The immunogenic composition according to claim 1 any one of claims 1 to 4, characterized in that the heterologous hydrophobic peptide is from an internal hydrophobic sequence.

### Claim 7 (depends on 1)

The immunogenic composition according to claim 1, characterized in that the heterologous hydrophobic peptide is from a C-terminal hydrophobic sequence.

### Claim 8 (depends on 7)

The immunogenic composition according to claim 7, characterized in that the C-terminal hydrophobic sequence is from decay accelerating factor (DAF).

### Claim 9 (depends on 1)

The immunogenic composition according to claim 1, characterized in that the saponin adjuvant is Quillaja saponin.

### Claim 10 (depends on 1)

A vaccine characterized in that it comprises an immunogenic composition according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

The vaccine according to claim 10, characterized in that it comprises at least one additional immunoactive component.

### Claim 12 (depends on 10)

The vaccine according claim 10, characterized in that it is in a freeze-dried form.

### Claim 13 (depends on 1, 10)

The method for the preparation of a vaccine according to claim 10, characterized in that the method comprises admixing an immunogenic composition according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 14

(canceled)
